NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

biosectinvestor, I think you are right. The current estimate of production capacity of annual vaccines to treat 450 to 500 patients per year is based on the current “clean room” technology, and it does not account for the increased optimization & efficiency that the Flaskworks system will provide.

So, the estimate of using only 5% of the current S.F. (4,400 S.F. out of 88,345 S.F.) and producing enough DCVax-L vaccines for up to 500 patients annually, is based on old clean room technology. Also, my estimate of using 100% of the square footage & producing enough DCVax-L vaccine for 10,000 patients a year, is based on current clean room Techonology, without Flaskworks.

By the way, I see the FUDsters are trying to say that NWBio does not have a CDMO agreement with Cognate / CRL anymore. They do not realize that the DCVax-L Phase III clinical trial has ended, and there is currently no commercial production of DCVax-L in the US because it has not been approved by the FDA & Health Canada yet.

But, that will change soon, and then Cognate / CRL will commence commercial production of DCVax-L soon.